288 related articles for article (PubMed ID: 31376034)
21. Outcomes of preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by esophagectomy in patients with resectable node-positive esophageal cancer.
Watanabe M; Baba Y; Yoshida N; Ishimoto T; Nagai Y; Iwatsuki M; Iwagami S; Baba H
Ann Surg Oncol; 2014 Sep; 21(9):2838-44. PubMed ID: 24715216
[TBL] [Abstract][Full Text] [Related]
22. Investigation of operative outcomes of thoracoscopic esophagectomy after triplet chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for advanced esophageal squamous cell carcinoma.
Akiyama Y; Iwaya T; Endo F; Chiba T; Takahara T; Otsuka K; Nitta H; Koeda K; Mizuno M; Kimura Y; Sasaki A
Surg Endosc; 2018 Jan; 32(1):391-399. PubMed ID: 28664431
[TBL] [Abstract][Full Text] [Related]
23. Advanced Age is Not a Contraindication for Treatment With Curative Intent in Esophageal Cancer.
Voncken FEM; van der Kaaij RT; Sikorska K; van Werkhoven E; van Dieren JM; Grootscholten C; Snaebjornsson P; van Sandick JW; Aleman BMP
Am J Clin Oncol; 2018 Sep; 41(9):919-926. PubMed ID: 28763327
[TBL] [Abstract][Full Text] [Related]
24. Docetaxel, Cisplatin, and 5-FU Triplet Therapy as Conversion Therapy for Locoregionally Advanced Unresectable Esophageal Squamous Cell Carcinoma.
Chan WL; Choi CW; Wong IY; Tsang TH; Lam AT; Tse RP; Chan KK; Wong C; Law BT; Cheung EE; Chan SY; Lam KO; Kwong D; Law S
Ann Surg Oncol; 2023 Feb; 30(2):861-870. PubMed ID: 36307666
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic strategy aiming at R0 resection for borderline-resectable esophageal squamous cell carcinoma using induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil.
Nakajima M; Muroi H; Kikuchi M; Kubo T; Inoue N; Ihara K; Nakagawa M; Morita S; Nakamura T; Kojima K
Gen Thorac Cardiovasc Surg; 2023 Oct; 71(10):584-590. PubMed ID: 37060435
[TBL] [Abstract][Full Text] [Related]
26. Induction chemoradiotherapy including docetaxel, cisplatin, and 5-fluorouracil for locally advanced esophageal cancer.
Hashimoto M; Shirakawa Y; Maeda N; Tanabe S; Noma K; Sakurama K; Katsui K; Nishizaki M; Fujiwara T
Esophagus; 2020 Apr; 17(2):127-134. PubMed ID: 31897761
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Docetaxel/Cisplatin/5-Fluorouracil Followed by Surgery.
Sugimura K; Miyata H; Shinno N; Ushigome H; Asukai K; Yanagimoto Y; Hasegawa S; Takahashi Y; Yamada D; Yamamoto K; Nishimura J; Motoori M; Wada H; Takahashi H; Yasui M; Omori T; Ohue M; Yano M
Oncology; 2019; 97(6):348-355. PubMed ID: 31461716
[TBL] [Abstract][Full Text] [Related]
28. Feasibility and efficiency of concurrent chemoradiotherapy with a single agent or double agents vs radiotherapy alone for elderly patients with esophageal squamous cell carcinoma: Experience of two centers.
Huang C; Zhu Y; Li Q; Zhang W; Liu H; Zhang W; Hu Y; Yuan Y; Liu M
Cancer Med; 2019 Jan; 8(1):28-39. PubMed ID: 30600600
[TBL] [Abstract][Full Text] [Related]
29. REG1A expression status suggests chemosensitivity among advanced thoracic esophageal squamous cell carcinoma patients treated with esophagectomy followed by adjuvant chemotherapy.
Sato Y; Motoyama S; Nanjo H; Ito S; Yoshino K; Sasaki T; Kuribayashi K; Nagaki Y; Imai K; Saito H; Minamiya Y; Ogawa J
Ann Surg Oncol; 2013 Sep; 20(9):3044-51. PubMed ID: 23645481
[TBL] [Abstract][Full Text] [Related]
30. A Phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246.
Swisher SG; Winter KA; Komaki RU; Ajani JA; Wu TT; Hofstetter WL; Konski AA; Willett CG
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1967-72. PubMed ID: 21507583
[TBL] [Abstract][Full Text] [Related]
31. Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma: The NEOCRTEC5010 Randomized Clinical Trial.
Yang H; Liu H; Chen Y; Zhu C; Fang W; Yu Z; Mao W; Xiang J; Han Y; Chen Z; Yang H; Wang J; Pang Q; Zheng X; Yang H; Li T; Zhang X; Li Q; Wang G; Chen B; Mao T; Kong M; Guo X; Lin T; Liu M; Fu J
JAMA Surg; 2021 Aug; 156(8):721-729. PubMed ID: 34160577
[TBL] [Abstract][Full Text] [Related]
32. Comparison of long-term outcomes between esophagectomy and chemoradiotherapy after endoscopic resection of submucosal esophageal squamous cell carcinoma.
Tanaka T; Ueno M; Iizuka T; Hoteya S; Haruta S; Udagawa H
Dis Esophagus; 2019 Dec; 32(12):. PubMed ID: 30980070
[TBL] [Abstract][Full Text] [Related]
33. Recurrence Pattern Comparing Preoperative Chemoradiotherapy and Preoperative Chemotherapy with Docetaxel plus 5-Fluorouracil and Cisplatin for Advanced Esophageal Cancer.
Sugase T; Sugimura K; Kanemura T; Takeoka T; Yamamoto M; Shinno N; Hara H; Omori T; Fujii Y; Mukai Y; Mikamori M; Hasegawa S; Haraguchi N; Akita H; Nishimura J; Wada H; Matsuda C; Yasui M; Miyata H
Oncology; 2022; 100(12):655-665. PubMed ID: 36198297
[TBL] [Abstract][Full Text] [Related]
34. Concurrent chemoradiotherapy with S-1 compared with concurrent chemoradiotherapy with docetaxel and cisplatin for locally advanced esophageal squamous cell carcinoma.
Zhou XL; Yu CH; Wang WW; Ji FZ; Xiong YZ; Zhu WG; Tong YS
Radiat Oncol; 2021 May; 16(1):94. PubMed ID: 34039375
[TBL] [Abstract][Full Text] [Related]
35. Induction immunotherapy plus chemotherapy followed by definitive chemoradiation therapy in locally advanced esophageal squamous cell carcinoma: a propensity-score matched study.
Lian HM; Wu JL; Liufu WJ; Yu TT; Niu SQ; Bao Y; Peng F
Cancer Immunol Immunother; 2024 Feb; 73(3):55. PubMed ID: 38366287
[TBL] [Abstract][Full Text] [Related]
36. Long-term results of concurrent chemoradiotherapy with daily-low-dose continuous infusion of 5-fluorouracil and cisplatin (LDFP) for Stage I-II esophageal carcinoma.
Kumabe A; Fukada J; Kota R; Koike N; Shiraishi Y; Seki S; Yoshida K; Kitagawa Y; Shigematsu N
Dis Esophagus; 2018 Apr; 31(4):. PubMed ID: 29228166
[TBL] [Abstract][Full Text] [Related]
37. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.
Kim S; François E; André T; Samalin E; Jary M; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Ghiringhelli F; Parzy A; De La Fouchardiere C; Smith D; Deberne M; Spehner L; Badet N; Adotevi O; Anota A; Meurisse A; Vernerey D; Taieb J; Vendrely V; Buecher B; Borg C
Lancet Oncol; 2018 Aug; 19(8):1094-1106. PubMed ID: 30042063
[TBL] [Abstract][Full Text] [Related]
38. Definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced cervical esophageal cancer.
Okamoto H; Taniyama Y; Sakurai T; Heishi T; Teshima J; Sato C; Maruyama S; Ito K; Onodera Y; Konno-Kumagai T; Ishida H; Kamei T
Esophagus; 2018 Oct; 15(4):281-285. PubMed ID: 29948480
[TBL] [Abstract][Full Text] [Related]
39. Radical esophagectomy for stage II and III thoracic esophageal squamous cell carcinoma followed by adjuvant radiotherapy with or without chemotherapy: Which is more beneficial?
Zou B; Tu Y; Liao D; Xu Y; Wang J; Huang M; Ren L; Zhu J; Gong Y; Liu Y; Zhou L; Zhou X; Peng F; Lu Y
Thorac Cancer; 2020 Mar; 11(3):631-639. PubMed ID: 31943824
[TBL] [Abstract][Full Text] [Related]
40. High pathologic complete remission rate from induction docetaxel, platinum and fluorouracil (DCF) combination chemotherapy for locally advanced esophageal and junctional cancer.
Noronha V; Joshi A; Jandyal S; Jambhekar N; Prabhash K
Med Oncol; 2014 Sep; 31(9):188. PubMed ID: 25148898
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]